DATA
Three Phase 1 studies: Total 111 healthy volunteers, 18-49 years old, weight 49-95 kg.
13% females, 28% East Asian (all males), 8% African-Americans, 50% administered capsules.
• Doses of 5-200 mg, administered as a single dose and/or QD for 5-10 days.
• Rich PK sampling -3627 eltrombopag concentrations.
• 88 ITP patients (83 from Phase 2 study, 5 from Phase 3 study), 18-85 years old, weight 43-122 kg.
65% females, 20% East Asian (of them 72% females), 100% administered tablets, 27% corticosteroid use.
• Doses of 30-75 mg QD administered for up to 6 weeks.
• Mix of sparse and serial PK sampling -466 eltrombopag concentrations.
•
METHODS

Population PK Modeling
Modeling was performed using a mixed-effects modeling approach with the first-order conditional method (FOCEI) of • NONMEM VI.
Model selection was driven by the data and was based on evaluation of goodness-of-fit plots, successful convergence, • plausibility and precision of parameter estimates, and the minimum objective function value.
Covariate modeling
Covariates selected based on the representation, range and correlation of covariate values in the dataset, scientific • interest, mechanistic plausibility, and exploratory graphics.
Covariates chosen for modeling: Weight, Population (Patients/healthy volunteers), Race, Gender, estimated creatinine • clearance (CRCL), Age, Concomitant use of corticosteroids, Formulation, and Low Dose (< 20 mg, standing for 5 mg capsule formulation).
Covariates modeled multiplicatively as power function.
for continuous covariates
for categorical covariates
The full model approach was implemented: all apriori chosen covariate-parameter relationships of interest were entered • in the model simultaneously, and parameters were estimated. Insignificant or poorly estimated covariates (based on confidence intervals (CI) of parameter estimates) could then be excluded from the model.
The full model did not simultaneously include highly correlated covariates; therefore several full models (with one of the • competing correlated covariates) were investigated.
Model evaluation
Visual predictive check simulations (VPC), overall and stratified by dose and study. 
RESULTS
Base model
2 compartment linear model with dual sequential first-order absorption, absorption lag-time, inter-occasion variability in absorption, and higher residual variability during absorption phase (Table 1) .
Covariate model
CL/F and Q/F, and Vc/F and Vp/F increased with Weight as power model (Figure 1 ).
• Change from 26% lower to 41% higher than for a 70-kg individual (weight range of 43 to 122 kg).
• Relationships shallower than allometric, although CI included (for CL/F) or nearly included (for Vc/F) allometric values.
• CL/F was influenced by East Asian Race > Corticosteroid intake > Sex > Population.
• 33% (CI 26%, 41%) lower in East Asians compared to all other races, • 26% (CI 7%, 45%) lower in patients taking corticosteroids concomitantly, • 19% (CI 7%, 31%) lower in females, • 17% (CI 0%, 34%) higher in healthy volunteers than in ITP patients.
• Due to correlations between covariates, AUCss increased 87% in East Asian patients, 50% in female patients, and 31% in • patients taking corticosteroids, compared to all patients, and decreased 35% in healthy volunteers compared to patients.
CL/F and Vc/F were 68% and 55% higher at low doses ( < 20 mg). 
Model evaluation
Graphical diagnostics (DV vs PRED, IPRED; WRES, IWRES vs PRED, TIME, TAD; distributions and correlations of • random effects, overall and stratified by study) did not show any deficiencies (Figure 2 ).
All covariate dependences observed in the base model were accounted for in the final model (Figure 3) . No unaccounted • relationships remained.
VPC: no bias evident; approximately 10% of observations outside 90% prediction intervals for each of doses and studies • (11% overall).
Nearly identical Nonmem and bootstrap point estimates and confidence intervals (Table 1) . •
CONCLUSIONS
The developed population pharmacokinetic model identified and quantified patient characteristics predictive of eltrombopag exposure, and enabled further analysis to characterize pharmacokinetic-pharmacodynamic relationships. constants prior to and after MTIME; Q/F = inter-compartmental clearance; Vp/F = volume of peripheral compartment; ALAG1 = lag-time; σ 2 prop and σ 2 add = proportional and additive components of the residual error model; σProp ~ITP and σProp ~TAD<4hr = factors of proportional error for ITP subjects and for TAD < 4 hours (absorption time); CI= confidence interval; R= correlation coefficient; ω 2 CL and ω 2 Vc = variances of random effect on CL/F and Vc/F; Covar ωCL, ωVc = correlation between covariances of CL/F and Vc/F random effects; ω 2 IOV Ka = variance of random IOV effect on Ka1; CV= coefficient of variation; SD = standard deviation
Parameter Estimates of Final Population Pharmacokinetic Model
Dependence of Oral Clearance on Weight for Different Subpopulations
Inter-individual Random Effect on CL/F versus Covariates
Goodness-of-fit plots for the Final Model
The reference population for PK parameters CL/F and Vc/F are 70 kg Caucasian male ITP patients not taking corticosteroids. CORT: corticosteroid use, 0=No, 1=Yes; ITP: 0= healthy volunteers, 1= patients; SEX: 0=females, 1=males; RACE: 0=Japanese, 1= non-Japanese East Asian, 2=Caucasian; 3 = Black; 4 = Other TAD= time after last dose
